文献速递糖尿病

初发2型糖尿病三联疗法与阶梯治疗的3年随访:EDICT研究

Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT.
PubMed 文献 · Diabetes Care · 2020-12-03

EDICT研究3年随访比较初发T2DM患者起始二甲双胍/吡格列酮/艾塞那肽三联治疗与阶梯添加二甲双胍、格列吡嗪和胰岛素的长期疗效。318例初治患者随机分组,三联治疗组3年HbA1c降幅更大且更持久,胰岛素敏感性和β细胞功能改善更显著。

要点

  • 三联治疗3年HbA1c为6.4%±0.1%,常规治疗为6.9%±0.1%,差异0.50%(95%CI 0.39-0.61;P<0.0001)。
  • 三联治疗使胰岛素敏感性增加三倍、β细胞功能增加30倍,常规治疗β细胞功能仅增加34%。
  • 三联治疗6个月HbA1c降幅即大于常规治疗(差值0.30%,95%CI 0.21-0.39;P=0.001)并维持至3年。

核心结论

  • 初发T2DM患者起始改善胰岛素敏感性和β细胞功能的三联治疗,比不纠正潜在代谢缺陷的降糖药物序贯治疗产生更大、更持久的HbA1c降幅。

研究设计与样本

  • EDICT研究3年随访,318例初治初发T2DM患者随机接受二甲双胍/吡格列酮/艾塞那肽三联治疗或二甲双胍后序贯加用格列吡嗪和胰岛素的常规治疗,目标HbA1c<6.5%(48 mmol/mol)。

主要发现

  • 三联治疗组和常规治疗组基线HbA1c±SEM分别为9.0%±0.2%和8.9%±0.2%。
  • 三联治疗6个月HbA1c降幅大于常规治疗(差值0.30%,95%CI 0.21-0.39;P=0.001),3年时差异为0.50%(95%CI 0.39-0.61;P<0.0001),尽管常规治疗组强化了降糖治疗。
  • 3年时三联治疗组HbA1c为6.4%±0.1%,常规治疗组为6.9%±0.1%。
  • 三联治疗使胰岛素敏感性增加三倍、β细胞功能增加30倍;常规治疗胰岛素敏感性无变化,β细胞功能仅增加34%(均P<0.0001 vs 三联治疗)。

临床怎么用

  • 对初发T2DM患者,起始联合改善胰岛素敏感性和β细胞功能的药物可能比阶梯添加降糖药获得更持久的血糖控制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the long-term efficacy of initiating therapy with metformin/pioglitazone/exenatide in patients with new-onset type 2 diabetes mellitus (T2DM) versus sequential addition of metformin followed by glipizide and insulin. RESEARCH DESIGN AND METHODS: Drug-naive patients (N = 318) with new-onset T2DM were randomly assigned to receive for 3 years either 1) combination therapy with metformin, pioglitazone, and exenatide (triple therapy) or 2) sequential addition of metformin followed by glipizide and insulin (conventional therapy) to maintain HbA1c at <6.5% (48 mmol/mol). Insulin sensitivity and β-cell function were measured at baseline and 3 years. The primary outcome was the difference in HbA1c between the groups at 3 years. RESULTS: Baseline HbA1c ± SEM values were 9.0% ± 0.2% and 8.9% ± 0.2% in the triple therapy and conventional therapy groups, respectively. The decrease in HbA1c resulting from triple therapy was greater at 6 months than that produced by conventional therapy (0.30% [95% CI 0.21-0.39]; P = 0.001), and the HbA1c reduction was maintained at 3 years in patients receiving triple therapy compared with conventional therapy (6.4% ± 0.1% and 6.9% ± 0.1%, respectively), despite intensification of antihyperglycemic therapy in the latter. Thus, the difference in HbA1c between the two treatment groups at 3 years was 0.50% (95% CI 0.39-0.61; P < 0.0001). Triple therapy produced a threefold increase in insulin sensitivity and 30-fold increase in β-cell function. In conventional therapy, insulin sensitivity did not change and β-cell function increased by only 34% (both P < 0.0001 vs. triple therapy). CONCLUSIONS: Triple therapy with agents that improve insulin sensitivity and β-cell function in patients with new-onset T2DM produces greater, more durable HbA1c reduction than agents that lower glucose levels without correcting the underlying metabolic defects.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Abdul-Ghani M, Puckett C, Adams J, et al. Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. Diabetes Care. 2020. PMID: 33273042. doi:10.2337/dc20-0978

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。